Document Classification

Section Type: RESULTS

Text: At the end of the 24-week follow-up, there were significant differences between the 48-week treatment group and the 72-week treatment group in patients with HBV DNA negativity (62. 3 % vs. 97. 0 %, x2 = 13. 273, P = 0. 000), HBeAg seroconversion (39. 6 % vs. 57. 6 %, x2 = 6. 765, P = 0. 009), HBsAg clearance (15. 1 % vs. 36. 4 %, x2 = 5. 155, P = 0. 023), and relapse (58. 5 % vs. 33. 3 %, x2 = 6. 713, P = 0. 010).